Systemic Co-Administration of Low-Dose Oxytocin and Glucagon-Like Peptide 1 Additively Decreases Food Intake and Body Weight.
Yuko MaejimaShoko YokotaShizu HidemaKatsuhiko NishimoriHeidi de WetKenju Shimomura
Published in: Neuroendocrinology (2024)
Chronic OXT/GLP-1 co-administration decreases BW, possibly via the activation of PVN OXT neurons. OXT might be a promising candidate as an incretin co-agonist in obesity treatment.